Catalyst Pharmaceuticals, Inc.
US ˙ NASDAQCM ˙ US14888U1016 ˙ Medical Devices
DIESES SYMBOL IST NICHT MEHR AKTIV

SecurityCPRX / Catalyst Pharmaceuticals, Inc.
InstitutionEQ ADVISORS TRUST - EQ/2000 Managed Volatility Portfolio Class IB
Latest Disclosed Ownership121,425 shares
Latest Disclosed Value $ 3,006,483
EQ ADVISORS TRUST - EQ/2000 Managed Volatility Portfolio Class IB reports 3.17% decrease in ownership of CPRX / Catalyst Pharmaceuticals, Inc.

On May 26, 2026 - EQ ADVISORS TRUST - EQ/2000 Managed Volatility Portfolio Class IB filed a NPORT-P form disclosing ownership of 121,425 shares of Catalyst Pharmaceuticals, Inc. (US:CPRX) valued at $3,006,483 USD as of March 31, 2026. The entity filed a previous NPORT-P on February 27, 2026 disclosing 125,404 shares of Catalyst Pharmaceuticals, Inc.. This represents a change in shares of -3.17% during the quarter. The current value of the position is $3,823,673 USD.

Institutional Ownership: 13F and NPORT Filings

The Security and Class in the table below are shown exactly as filed by the investor. We do our best to track continuity of investments through acquisitions, and this will be reflected in the table as changes in names. In addition to descriptive data, performance of the investment is shown over time. To calculate quarterly performance, we first calculate cost basis of the shares purchased during the quarter, then use that to calculate gross profit. Quarterly return is Gross Profit / Starting Portfolio value.

Note that cost basis is calculated and stored in thousands, so small quarterly changes in shares frequently result in a cost basis of zero.

Upgrade to unlock premium data and export to Excel .

Disclosed Equity Positions (from 13F/NPORT Filings)
File
Date		 Effective
Date		Form Security Class ID Avg Price
Paid (Est)		 Reported
Shares		 ΔShares ΔShares
(%)		 Reported
Value
(x1000)		 ΔValue
(%)		 Alloc
(%)		 ΔAlloc ΔAlloc (%) Cost Basis
(x1000)		 Unrealized
Gain/Loss
(x1000)
2026-05-26 2026-03-31 NP Catalyst Pharmaceuticals EC US14888U1016 121,425 -3,979 -3.17 3,006 2.73 0.0887
2026-02-27 2025-12-31 NP Catalyst Pharmaceuticals EC US14888U1016 125,404 -6,353 -4.82 2,927 12.76 0.0842
2025-11-25 2025-09-30 NP Catalyst Pharmaceuticals EC US14888U1016 131,757 -3,236 -2.40 2,596 -11.40 0.0724
2025-08-26 2025-06-30 NP Catalyst Pharmaceuticals EC US14888U1016 134,993 4,817 3.70 2,929 -7.19 0.0892
2025-05-23 2025-03-31 NP Catalyst Pharmaceuticals EC US14888U1016 130,176 0 0.00 3,157 16.20 0.1025
2025-02-27 2024-12-31 NP Catalyst Pharmaceuticals EC US14888U1016 130,176 -4,685 -3.47 2,717 1.31 0.0787
2024-11-27 2024-09-30 NP Catalyst Pharmaceuticals EC US14888U1016 134,861 7,137 5.59 2,681 35.54 0.0750
2024-08-26 2024-06-30 NP Catalyst Pharmaceuticals EC US14888U1016 127,724 3,368 2.71 1,978 -0.20 0.0588
2024-05-23 2024-03-31 NP Catalyst Pharmaceuticals EC US14888U1016 124,356 7,604 6.51 1,982 1.02 0.0600
2024-02-27 2023-12-31 NP Catalyst Pharmaceuticals EC US14888U1016 116,752 3,494 3.08 1,963 48.30 0.0598
2023-11-27 2023-09-30 NP Catalyst Pharmaceuticals EC US14888U1016 113,258 -7,353 -6.10 1,324 -18.38 0.0459
2023-08-25 2023-06-30 NP Catalyst Pharmaceuticals EC US14888U1016 120,611 -2,322 -1.89 1,621 -20.46 0.0504
2023-05-30 2023-03-31 NP Catalyst Pharmaceuticals EC US14888U1016 122,933 0 0.00 2,038 -10.85 0.0644
2023-03-01 2022-12-31 NP Catalyst Pharmaceuticals EC US14888U1016 122,933 -7,705 -5.90 2,287 36.40 0.0717
2022-11-28 2022-09-30 NP Catalyst Pharmaceuticals EC US14888U1016 130,638 0 0.00 1,676 83.17 0.0529
2022-08-24 2022-06-30 NP Catalyst Pharmaceuticals EC US14888U1016 130,638 0 0.00 916 -15.43 0.0268
2022-05-27 2022-03-31 NP Catalyst Pharmaceuticals EC US14888U1016 130,638 0 0.00 1,083 22.40 0.0269
2022-02-28 2021-12-31 NP Catalyst Pharmaceuticals EC US14888U1016 130,638 0 0.00 884 27.75 0.0200
2021-11-26 2021-09-30 NP Catalyst Pharmaceuticals EC US14888U1016 130,638 0 0.00 692 -7.86 0.0152
2021-08-25 2021-06-30 NP Catalyst Pharmaceuticals EC US14888U1016 130,638 0 0.00 751 24.75 0.0153
2021-05-28 2021-03-31 NP Catalyst Pharmaceuticals EC US14888U1016 130,638 -50,309 -27.80 602 -0.33 0.0127
2021-02-24 2020-12-31 NP Catalyst Pharmaceuticals EC US14888U1016 180,947 0 0.00 604 12.48 0.0129
2020-11-27 2020-09-30 NP Catalyst Pharmaceuticals EC US14888U1016 180,947 0 0.00 537 -35.69 0.0141
2020-08-25 2020-06-30 NP Catalyst Pharmaceuticals EC US14888U1016 180,947 19,313 11.95 836 34.24 0.0217
2020-05-28 2020-03-31 NP Catalyst Pharmaceuticals EC US14888U1016 161,634 0 0.00 622 2.64 0.0198
2020-02-24 2019-12-31 NP Catalyst Pharmaceuticals EC 14888U101 161,634 0 0.00 606 -29.37 0.0157
2019-11-27 2019-09-30 NP Catalyst Pharmaceuticals EC US14888U1016 161,634 161,634 858 0.0239
Legend
Shares
The total number of shares held by the institution at the end of the reporting period (the effective date). This is provided in the filing.
Value
The total value of the shares as of the effective date. This is provided in the filing.
Avg. Share Price
The weighted average share price of the shares held by the institution. We use FIFO accounting to determine this price
Class
This is the security class as indicated by the filer. There are a variety of values for this field. Common values include "EC" = equity common, "EP" - equity preferred
Allocation (%)
The percent of the institution's portfolio that this position represents. This is provided in NPORT filings. For 13F filings, we calculate it.
Change in Allocation
The change in allocation from the prior reporting period. This is calculated as current allocation - prior allocation.
Change in Allocation (%)
The percent change in allocation from the prior reporting period. This is calculated as (current allocation - prior allocation) / prior allocation.
Cost Basis
The total cost of the shares held. This is calculated as reported shares * avg. share price
Unrealized Gain/Loss
This is the market value of the position as of the effective date minus the cost basis.